Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Financing Activities (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Cash from Financing Activities for 2 consecutive years, with $24.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 73464.71% to $24.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.8 million through Dec 2025, up 20780.0% year-over-year, with the annual reading at $24.8 million for FY2025, 20780.0% up from the prior year.
  • Cash from Financing Activities hit $24.9 million in Q4 2025 for Prelude Therapeutics, up from -$5000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $24.9 million in Q4 2025 to a low of -$160000.0 in Q1 2025.